Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Oct 25th, 2023

Late-Breaking Science and Featured Science for Sunday

Today's Late-Breaking Science sessions focus on atrial fibrillation and novel approaches to lipid-lowering therapies.


standing ovation by the audience at a Main Event

LBS.05: Shocking Decisions in AFib Care

8-9:15 a.m. | Main Event I

• Efficacy and Safety of Dual Direct Current Cardioversion Versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients With Atrial Fibrillation

• Abelacimab, a Novel Factor XI/XIa Inhibitor, Versus Rivaroxaban in Patients With Atrial Fibrillation: Primary Results of the AZALEATIMI 71 Randomized Trial (AZALEA-TIMI 71)

• Efficacy and Safety of Anticoagulation With Edoxaban in Patients With AHRE Durations ≥24 Hours: The NOAH-AFNET 6 Trial (NOAH-AFNET 6)

• Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation (ARTESIA)

LBS.06: Future of Lipid-Lowering Therapy — Novel Mechanisms and Approaches

3:30-4:45 p.m. | Main Event I

• Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

• Recaticimab Add-On Therapy in Patients With Non-Familial Hypercholesterolaemia and Mixed Hyperlipidemia (REMAIN-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial (REMAIN-2)

• Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein (a)

• Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol—Interim Results of the Phase 1b heart-1 Trial (VERVE-101)

Featured Science for Sunday

New Approaches to CV Therapeutics—First in Human Treatments

8-9:15 a.m.

HFpEF and Amyloid—It’s Prime Time!

9:45-11 a.m.


Interesting Stories
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
More Content
Maxresdefault 65561fbdb9acc
AHA23
Watch: Scientific Sessions 2023 Day 2 | Sunday, Nov. 12
Nov 16th, 2023
Panel of speakers
AHA23
Getting to the Heart of Stroke™
Nov 15th, 2023
Hqdefault 6554fd1be4044
AHA23
Watch: Scientific Sessions 2023 | Day 1, Saturday, Nov. 11
Nov 15th, 2023
Maxresdefault 6554fad25bb7c
AHA23
Watch: Scientific Sessions 2023 Pre-Sessions Symposia & Early Career Day
Nov 15th, 2023
Audience shot
AHA23
Late-breaking science| Achieving equity in prevention
Nov 15th, 2023
audience shot
AHA23
Novel mechanisms for lipid-lowering therapy
Nov 14th, 2023
LBS 08 panelists
AHA23
Late-breaking science: AI at the bedside
Nov 14th, 2023
Lbs05 Panel Web
AHA23
Shocking decisions in AFib care
Nov 13th, 2023
Lbs04 Panel2 Web
AHA23
Drugs, diet and delivery can optimize hypertension outcomes
Nov 13th, 2023
Jane E. Freedman, MD, Ann Marie Schmidt, MD, M. Benjamin Shoemaker, MD, MSCI, J. Kevin Donahue, MD
AHA23
Established lecture to present new research developments
Nov 13th, 2023
Randi Foraker, PhD, MA, FAHA, FAMIA, Jessica L. Mega, MD, MPH
AHA23
Artificial intelligence shows promise and pitfalls
Nov 13th, 2023
Clyde W. Yancy, MD, MSc, MACC, FAHA, and Reinier Boon, PhD
AHA23
Age: Is it a number, or a biology?
Nov 13th, 2023